Atlas Trials

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Clinical trial NCT04687072 · COMPLETED

Trial details

NCT number
NCT04687072
Sponsor
argenx
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Primary Immune Thrombocytopenia
Start date
2020-12-16
Primary completion
2023-10-09
Enrollment
207

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.